article thumbnail

3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev

Fierce Pharma

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in (..)

FDA 317
article thumbnail

Pfizer settles gender pay discrimination allegations at NYC headquarters

Fierce Pharma

The accusations centered on the company's compensation of 86 female employees in 2015 and 2016. Department of Labor that it underpaid certain women who were employed at the company’s New York City headquarters. |

317
317
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How high-intent platforms help pharma brands engage action-oriented customers

Fierce Pharma

Way back in 2015 a post on the Think with Google blog made the bold claim that, for marketers, consumer intent is more powerful than demographics: “Intent beats identity. GoodRx is a trusted, high-intent platform that helps providers and patients find what they need at the exact moment they are looking for something.

Pharma 264
article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017.

Medicine 271
article thumbnail

At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy

MedCity News

Though GSK divested much of its oncology assets to Novartis in 2015, the company has built it back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P.

article thumbnail

Mallinckrodt sells Therakos unit on at a discount

pharmaphorum

Mallinckrodt agrees to sell Therakos to private equity firm CVC $925m, well below the $1.33bn it paid for the business in 2015

105
105
article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

In a 2015 study of 36 cancer drugs that had recently been approved, only 5 showed extended life. It’s about getting approvals and then making money and efficacy data be damned. The drug industry is driven by profits, not by patient’s needs. Here’s another example. That is reprehensible.

Pharma 292